Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial.
about
Bladder Preservation for Muscle Invasive Bladder CancerPrognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-AnalysisExpression of hypoxia-inducible factor-1α predicts benefit from hypoxia modification in invasive bladder cancerPrimary tumor inflammation in gross tumor volume as a prognostic factor for nasopharyngeal carcinoma patientsExpression of miR-210 in relation to other measures of hypoxia and prediction of benefit from hypoxia modification in patients with bladder cancer.A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer.Selective organ preservation for the treatment of muscle-invasive transitional cell carcinoma of the bladder: a review of current and future perspectives.FMISO as a Biomarker for Clinical Radiation Oncology.Pre-treatment lymphocytopaenia is an adverse prognostic biomarker in muscle-invasive and advanced bladder cancer.The anti-PD-1 era - an opportunity to enhance radiotherapy for patients with bladder cancer.Assessment of tumor necrotic fraction by dynamic contrast-enhanced MRI: a preclinical study of human tumor xenografts with histopathologic correlation.The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004).Targeting tumour hypoxia to improve outcome of stereotactic radiotherapy.Identification of hypoxic gene-signature as a prognostic and predictive biomarker to determine effective therapy in high risk bladder cancer patients.Biomarkers for Predicting Clinical Outcomes of Chemoradiation-Based Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer
P2860
Q26744750-3A5206B4-1016-4CD5-8544-3C3B01B88EB1Q26749393-6072AE8E-0AEB-47A0-A6B4-271B0EF05F75Q33994365-058B68BD-125D-48CD-B837-CF180B51ED07Q37046765-BFF55365-F14F-4EB9-AF4F-6F4E8EC8B78EQ37203114-F0E5CC17-6052-44B6-815B-05E02B2B0CE7Q37231848-B893959C-95C3-43DF-BF21-7D8C6F0A2893Q38255032-062883CB-7DAD-405D-B266-1CFFBC4FF42EQ38869449-54437F10-B5EB-4BFF-8E04-06CF1BFBC254Q41116973-23982406-66A8-481D-81E8-F4AB4BA8B573Q47580489-0BF9ECEB-ED12-415B-9EDA-BE56FD6F623BQ51111027-CD413C56-D88A-412C-8836-28E89389F567Q51167495-3B2D93D3-1824-427B-9281-8F6AF5903458Q51598914-9CC8FC4B-A772-4815-A2CB-D1E167673184Q55128172-C63602DF-2B67-40DE-8A04-2149DA54F54BQ58736803-FB179AC9-BF2B-47A2-A495-D63C58641EEF
P2860
Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Necrosis predicts benefit from ...... a phase III randomised trial.
@en
Necrosis predicts benefit from ...... a phase III randomised trial.
@nl
type
label
Necrosis predicts benefit from ...... a phase III randomised trial.
@en
Necrosis predicts benefit from ...... a phase III randomised trial.
@nl
prefLabel
Necrosis predicts benefit from ...... a phase III randomised trial.
@en
Necrosis predicts benefit from ...... a phase III randomised trial.
@nl
P2093
P2860
P50
P1476
Necrosis predicts benefit from ...... n a phase III randomised trial
@en
P2093
Amanda Eustace
Ana M Rojas
David Ryder
Helen Denley
Janet Taylor
Joely J Irlam
Jonathan J Ord
Peter J Hoskin
Shailesh Agrawal
P2860
P356
10.1016/J.RADONC.2013.05.017
P577
2013-06-14T00:00:00Z